Open Payments

CALIFORNIA PACIFIC MEDICAL CENTER

Type
Teaching hospital
Where
San Francisco, CA
Medicare CCN
050047
Received
$1,656,051 in 68 records, 2024 ($44,085 general, $1,611,966 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2024General payment22$44,085
2024Research payment46$1,611,966

By company

CompanyRecordsAmountYears
Merck Sharp & Dohme LLC12$1,340,9922024
ModernaTX, Inc.6$113,0192024
Genentech, Inc.9$79,7272024
Stryker Corporation17$37,0152024
PTC Therapeutics, Inc.4$30,3912024
Regeneron Pharmaceuticals, Inc.5$18,8282024
ABBVIE INC.4$17,4122024
Boston Scientific Corporation4$6,1082024
Medtronic, Inc.2$5,9842024
Novartis Pharmaceuticals Corporation1$2,5002024
GT Medical Technologies, Inc1$2,0002024
Micro-tech Endoscopy USA, Inc.2$1,7072024
Medline Industries LP1$3622024

By nature of payment

NatureRecordsAmount
Research payment46$1,611,966
Long term medical supply or device loan19$38,722
Space rental or facility fees (teaching hospital only)2$5,000
Debt forgiveness1$362

Records

DateCompanyAmountNatureFormProductStudyYear
2024-12-31Merck Sharp & Dohme LLC$541,826Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYSTUDY NAME#Phase II study of olaparib in combination with pembrolizumab in patients with advanced melanoma with homologo2024
2024-12-31Merck Sharp & Dohme LLC$282,985Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK 7684A Vibostolimab with 2024
2024-12-31Merck Sharp & Dohme LLC$43,197Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYAdjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection 2024
2024-12-31Merck Sharp & Dohme LLC$16,898Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPhase Ib,II Trial of Pembrolizumab MK-3475 Combination Therapies in Metastatic Castration-Resistant Prostate Cancer mCRP2024
2024-12-31Merck Sharp & Dohme LLC$11,145Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 and Lenvatin2024
2024-12-31Stryker Corporation$6,533Long term medical supply or device loanIn-kind items and servicesNA Device, INSTRUMENTS2024
2024-12-31Merck Sharp & Dohme LLC$4,438Research paymentIn-kind items and services Biological, ONCOLOGYA Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Mo2024
2024-12-31Stryker Corporation$3,785Long term medical supply or device loanIn-kind items and servicesNA Device, INSTRUMENTS2024
2024-12-31Stryker Corporation$3,785Long term medical supply or device loanIn-kind items and servicesNA Device, INSTRUMENTS2024
2024-12-31Stryker Corporation$3,686Long term medical supply or device loanIn-kind items and servicesNA Device, INSTRUMENTS2024
2024-12-31Stryker Corporation$3,234Long term medical supply or device loanIn-kind items and servicesNA Device, INSTRUMENTS2024
2024-12-31Merck Sharp & Dohme LLC$3,143Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYAdjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection 2024
2024-12-31Stryker Corporation$2,788Long term medical supply or device loanIn-kind items and servicesNA Device, INSTRUMENTS2024
2024-12-31Stryker Corporation$2,230Long term medical supply or device loanIn-kind items and servicesRemB Device, INSTRUMENTS2024
2024-12-31Stryker Corporation$2,065Long term medical supply or device loanIn-kind items and servicesNA Device, INSTRUMENTS2024
2024-12-31Stryker Corporation$1,627Long term medical supply or device loanIn-kind items and servicesNA Device, INSTRUMENTS2024
2024-12-31Stryker Corporation$1,511Long term medical supply or device loanIn-kind items and servicesNA Device, INSTRUMENTS2024
2024-12-31Stryker Corporation$958Long term medical supply or device loanIn-kind items and servicesRemB Device, INSTRUMENTS2024
2024-12-31Stryker Corporation$958Long term medical supply or device loanIn-kind items and servicesRemB Device, INSTRUMENTS2024
2024-12-31Stryker Corporation$944Long term medical supply or device loanIn-kind items and servicesNA Device, INSTRUMENTS2024
2024-12-31Stryker Corporation$744Long term medical supply or device loanIn-kind items and servicesNA Device, INSTRUMENTS2024
2024-12-31Stryker Corporation$719Long term medical supply or device loanIn-kind items and servicesRemB Device, INSTRUMENTS2024
2024-12-31Stryker Corporation$719Long term medical supply or device loanIn-kind items and servicesRemB Device, INSTRUMENTS2024
2024-12-31Stryker Corporation$719Long term medical supply or device loanIn-kind items and servicesRemB Device, INSTRUMENTS2024
2024-12-31Medline Industries LP$362Debt forgivenessCash or cash equivalent2024
2024-12-17Medtronic, Inc.$1,150Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsOptimize Pro2024
2024-11-06Merck Sharp & Dohme LLC$127,506Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYSTUDY NAME#Sentinel Lymph Nodes# Immune Response to Melanoma and Implications to Survival and Therapy Outcomes with pemb2024
2024-10-20Micro-tech Endoscopy USA, Inc.$853Long term medical supply or device loan (26 payments)In-kind items and servicesEL27-Compact Electrohydraulic Lithotripter Device, Gastroenterology2024
2024-10-20Micro-tech Endoscopy USA, Inc.$853Long term medical supply or device loan (26 payments)In-kind items and servicesHD Digital Controller for eyeMAX PB Device, Gastroenterology2024
2024-10-16ModernaTX, Inc.$19,051Research paymentCash or cash equivalentA Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Ve2024
2024-10-16ModernaTX, Inc.$8,243Research paymentCash or cash equivalentA Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Ve2024
2024-10-16ModernaTX, Inc.$3,645Research paymentCash or cash equivalentA Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Ve2024
2024-10-09Regeneron Pharmaceuticals, Inc.$14,673Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2024
2024-10-09Regeneron Pharmaceuticals, Inc.$2,497Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2024
2024-10-01GT Medical Technologies, Inc$2,000Research paymentCash or cash equivalentGammaTile Device, KXKGTM-1012024
2024-09-30Merck Sharp & Dohme LLC$1,972Research paymentIn-kind items and services Biological, ONCOLOGYA Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Mo2024
2024-09-25ModernaTX, Inc.$3,280Research paymentCash or cash equivalentA Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Ve2024
2024-09-18Regeneron Pharmaceuticals, Inc.$1,100Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2024
2024-09-18Regeneron Pharmaceuticals, Inc.$500Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2024
2024-09-04ABBVIE INC.$1,075Research paymentCash or cash equivalentStudy to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Co2024
2024-08-05PTC Therapeutics, Inc.$3,804Research paymentCash or cash equivalentA PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK2024
2024-07-23Boston Scientific Corporation$1,221Research paymentCash or cash equivalentWATCHMAN Access System Device, WATCHMAN_ICOPTION2024
2024-07-09Genentech, Inc.$34,973Research paymentCash or cash equivalentPhase Ib belvarafenib alone and in combo with cobi or cobi atezo in NRAS m adv melanoma patients2024
2024-07-02Regeneron Pharmaceuticals, Inc.$57Research paymentCash or cash equivalentLIBTAYO Biological, ONCOLOGYA PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A2024
2024-06-26ModernaTX, Inc.$51,236Research paymentCash or cash equivalentA Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Ve2024
2024-06-25Boston Scientific Corporation$1,221Research paymentCash or cash equivalentWATCHMAN Access System Device, WATCHMAN_ICOPTION2024
2024-06-12Medtronic, Inc.$4,834Research paymentCash or cash equivalentONYX 18 Device, Liquid EmbolicsEMBOLISE2024
2024-06-06ABBVIE INC.$1,719Research paymentCash or cash equivalentStudy to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Co2024
2024-06-05PTC Therapeutics, Inc.$10,239Research paymentCash or cash equivalentA PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK2024
2024-05-27Merck Sharp & Dohme LLC$149,799Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYPhase II study of olaparib in combination with pembrolizumab in patients with advanced melanoma with homologous recombin2024
2024-05-22Merck Sharp & Dohme LLC$155,579Research paymentCash or cash equivalentLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 and Lenvatin2024
2024-05-09ABBVIE INC.$13,773Research paymentCash or cash equivalentStudy to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused With Livmoniplimab in Co2024
2024-04-22Boston Scientific Corporation$1,221Research paymentCash or cash equivalentWATCHMAN Access System Device, WATCHMAN_ICOPTION2024
2024-04-19Merck Sharp & Dohme LLC$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentKEYTRUDA Biological, ONCOLOGY2024
2024-04-19Novartis Pharmaceuticals Corporation$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentKISQALI Drug, Oncology2024
2024-04-03PTC Therapeutics, Inc.$10,714Research paymentCash or cash equivalentA PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK2024
2024-04-03PTC Therapeutics, Inc.$5,633Research paymentCash or cash equivalentA PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK2024
2024-03-07ABBVIE INC.$843Research paymentCash or cash equivalentStudy to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in 2024
2024-03-06Genentech, Inc.$14,800Research paymentCash or cash equivalentPhase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC2024
2024-03-06Genentech, Inc.$8,773Research paymentCash or cash equivalentPhase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC2024
2024-03-06Genentech, Inc.$3,500Research paymentCash or cash equivalentPhase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC2024
2024-03-06Genentech, Inc.$1,500Research paymentCash or cash equivalentPhase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC2024
2024-03-06Genentech, Inc.$1,000Research paymentCash or cash equivalentPhase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC2024
2024-03-06Genentech, Inc.$500Research paymentCash or cash equivalentPhase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC2024
2024-02-20Genentech, Inc.$4,240Research paymentCash or cash equivalentPhase Ib belvarafenib alone and in combo with cobi or cobi atezo in NRAS m adv melanoma patients2024
2024-02-02ModernaTX, Inc.$27,562Research paymentCash or cash equivalentA Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Ve2024
2024-01-22Boston Scientific Corporation$2,443Research paymentCash or cash equivalentWATCHMAN Access System Device, WATCHMAN_ICOPTION2024
2024-01-11Genentech, Inc.$10,441Research paymentCash or cash equivalentPhase Ib belvarafenib alone and in combo with cobi or cobi atezo in NRAS m adv melanoma patients2024

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

San Francisco CountySan Francisco city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In San Francisco, CA, county San Francisco County, CA, state California; placed by its city name.

MeasurePlace (city or town)
San Francisco, CA
County
San Francisco County, CA
State
California
Population B01003830,235830,23539,287,377
Population, 2020 census P1873,965873,96539,538,223
Median age B0100240.040.037.9
Under 18 B0100113.7%13.7%22.0%
65 and over B0100117.6%17.6%15.7%
Households B11001363,970363,97013,548,091
Foreign born B0500234.0%34.0%27.0%
Median household income B19013$140,970$140,970$99,122
Median family income B19113$171,141$171,141$113,346
Per capita income B19301$92,289$92,289$49,513
Poverty rate B1700111.2%11.2%12.0%
Unemployment rate B230256.1%6.1%6.6%
Civilian labor force B23025507,262507,26220,068,466
Mean commute (minutes) B0801330.430.428.7
Bachelor's degree or higher B1500360.3%60.3%37.1%
Housing units B25001414,602414,60214,644,735
Owner-occupied B2500338.2%38.2%55.9%
Renters B2500361.8%61.8%44.1%
Median home value B25077$1,394,500$1,394,500$734,700
Median gross rent B25064$2,476$2,476$2,036
White, not Hispanic B0300236.8%36.8%33.8%
Black B030024.7%4.7%5.2%
Hispanic or Latino B0300216.2%16.2%40.2%
Asian B0300234.9%34.9%15.3%
American Indian and Alaska Native B030020.2%0.2%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.0% in Oct 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in San Francisco, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.